$ESPR
Esperion Therapeutics, Inc. Stock $espr

$espr Overview Financials Valuation SEC Filings Company Website

2020 Q4 Form 10-K Financial Statement

#000162828021002865 Filed on February 23, 2021

Income Statement

Concept	2020 Q4	2020 Q1	2020
Revenue	$9.638M	$1.840M	$227.5M
YoY Change	881.47%	-98.73%	53.37%
Cost Of Revenue	$1.700M	$0.00	$2.400M
YoY Change
Gross Profit	$8.000M	$1.800M	$225.2M
YoY Change
Gross Profit Margin	83.0%	97.83%	98.97%
Selling, General & Admin	$61.56M	$41.55M	$199.6M
YoY Change	183.66%	241.1%	203.12%
% of Gross Profit	769.44%	2308.5%	88.64%
Research & Development	$41.96M	$34.70M	$146.9M
YoY Change	9.76%	-25.06%	-16.33%
% of Gross Profit	524.55%	1927.89%	65.25%
Depreciation & Amortization	$160.0K	$106.0K	$500.0K
YoY Change	60.0%	49.3%	66.67%
% of Gross Profit	2.0%	5.89%	0.22%
Operating Expenses	$105.2M	$76.29M	$348.9M
YoY Change	75.5%	30.43%	44.51%
Operating Profit	-$95.57M	-$74.45M	-$121.4M
YoY Change	62.08%	-185.64%	30.39%
Interest Expense	$8.931M	$4.171M	$22.67M
YoY Change	116.56%		179.19%
% of Operating Profit
Other Income/Expense, Net	$24.00K	$368.0K	$515.0K
YoY Change	-97.9%	-18.22%	-87.3%
Pretax Income	-$104.5M	-$78.20M	-$143.6M
YoY Change	68.82%	-189.47%	47.74%
Income Tax		$0.00	$0.00
% Of Pretax Income
Net Earnings	-$104.5M	-$78.25M	-$143.6M
YoY Change	68.66%	-189.55%	47.74%
Net Earnings / Revenue	-1084.0%	-4252.66%	-63.09%
Basic Earnings Per Share	-$3.89	-$2.84	-$5.23
Diluted Earnings Per Share	-$3.89	-$2.84	-$5.23
COMMON SHARES
Basic Shares Outstanding	26.88M shares	27.52M shares	27.47M shares
Diluted Shares Outstanding	26.88M shares	27.52M shares	27.47M shares

Balance Sheet

Concept	2020 Q4	2020 Q1	2020
SHORT-TERM ASSETS
Cash & Short-Term Investments	$305.0M	$157.3M	$305.0M
YoY Change	51.89%	-31.15%	51.89%
Cash & Equivalents	$305.0M	$149.4M	$305.0M
Short-Term Investments	$0.00	$7.931M	$0.00
Other Short-Term Assets	$24.80M	$13.40M	$24.80M
YoY Change	127.52%	100.0%	127.52%
Inventory	$16.14M	$1.841M	$16.10M
Prepaid Expenses
Receivables	$12.39M
Other Receivables
Total Short-Term Assets	$345.9M	$172.6M	$345.9M
YoY Change	63.38%	-26.6%	63.39%
LONG-TERM ASSETS
Property, Plant & Equipment	$1.276M	$1.447M	$7.300M
YoY Change	11.44%	20.58%	170.37%
Goodwill
YoY Change
Intangibles	$56.00K
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets	$7.362M	$7.013M	$7.400M
YoY Change	169.37%	439.46%	174.07%
TOTAL ASSETS
Total Short-Term Assets	$345.9M	$172.6M	$345.9M
Total Long-Term Assets	$7.362M	$7.013M	$7.400M
Total Assets	$353.3M	$179.6M	$353.3M
YoY Change	64.73%	-24.04%	64.79%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$51.98M	$15.11M	$52.00M
YoY Change	80.12%	-54.61%	79.93%
Accrued Expenses	$35.00M	$48.20M	$35.00M
YoY Change	17.45%	111.4%	17.45%
Deferred Revenue	$1.662M	$1.170M
YoY Change	-22.77%
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$94.07M	$73.45M	$94.10M
YoY Change	42.36%	22.42%	42.36%
LONG-TERM LIABILITIES
Long-Term Debt	$179.4M	$0.00	$179.4M
YoY Change
Other Long-Term Liabilities	$1.290M	$156.4M	$176.0M
YoY Change		11071.43%	37.07%
Total Long-Term Liabilities	$1.290M	$156.4M	$355.4M
YoY Change		11071.43%	176.79%
TOTAL LIABILITIES
Total Short-Term Liabilities	$94.07M	$73.45M	$94.10M
Total Long-Term Liabilities	$1.290M	$156.4M	$355.4M
Total Liabilities	$449.4M	$229.9M	$449.4M
YoY Change	131.05%	273.8%	131.05%
SHAREHOLDERS EQUITY
Retained Earnings	-$838.8M	-$773.5M
YoY Change	20.65%
Common Stock	$26.00K	$28.00K
YoY Change	-3.7%
Preferred Stock
YoY Change
Treasury Stock (at cost)	$55.00M
YoY Change
Treasury Stock Shares	1.994M shares
Shareholders Equity	-$96.13M	-$50.25M	-$96.10M
YoY Change
Total Liabilities & Shareholders Equity	$353.3M	$179.6M	$353.3M
YoY Change	64.73%	-24.04%	64.79%

Cashflow Statement

Concept	2020 Q4	2020 Q1	2020
OPERATING ACTIVITIES
Net Income	-$104.5M	-$78.25M	-$143.6M
YoY Change	68.66%	-189.55%	47.74%
Depreciation, Depletion And Amortization	$160.0K	$106.0K	$500.0K
YoY Change	60.0%	49.3%	66.67%
Cash From Operating Activities	-$68.55M	-$69.35M	-$85.18M
YoY Change	37.13%	-175.63%	21.09%
INVESTING ACTIVITIES
Capital Expenditures	-$12.68M	$191.0K	$869.0K
YoY Change	7358.82%	1.06%	-8.81%
Acquisitions
YoY Change
Other Investing Activities	$0.00	$26.78M	$34.73M
YoY Change	-100.0%	-41.64%	-46.72%
Cash From Investing Activities	-$12.67M	$26.59M	$21.36M
YoY Change	341.46%	-41.81%	-66.75%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net	$55.00M		$55.00M
YoY Change
Debt Paid & Issued, Net			$0.00
YoY Change
Cash From Financing Activities	170.4M	$26.01M	$201.7M
YoY Change	2327.92%	1458.66%	48.11%
NET CHANGE
Cash From Operating Activities	-68.55M	-$69.35M	-$85.18M
Cash From Investing Activities	-12.67M	$26.59M	$21.36M
Cash From Financing Activities	170.4M	$26.01M	$201.7M
Net Change In Cash	89.22M	-$16.74M	$137.9M
YoY Change	-294.63%	-112.04%	6.01%
FREE CASH FLOW
Cash From Operating Activities	-$68.55M	-$69.35M	-$85.18M
Capital Expenditures	-$12.68M	$191.0K	$869.0K
Free Cash Flow	-$55.87M	-$69.54M	-$86.05M
YoY Change	12.14%	-176.0%	20.69%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2020	dei	Entity Central Index Key EntityCentralIndexKey	0001434868
CY2020	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2020
CY2020	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2020	dei	Amendment Flag AmendmentFlag	false
CY2020	dei	Document Type DocumentType	10-K
CY2020	dei	Document Annual Report DocumentAnnualReport	true
CY2020	dei	Document Period End Date DocumentPeriodEndDate	2020-12-31
CY2020	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2020	dei	Document Transition Report DocumentTransitionReport	false
CY2020	dei	Entity File Number EntityFileNumber	001-35986
CY2020	dei	Entity Registrant Name EntityRegistrantName	Esperion Therapeutics, Inc.
CY2020	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2020	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	26-1870780
CY2020	dei	Entity Address Address Line1 EntityAddressAddressLine1	3891 Ranchero Drive, Suite 150
CY2020	dei	Entity Address City Or Town EntityAddressCityOrTown	Ann Arbor
CY2020	dei	Entity Address State Or Province EntityAddressStateOrProvince	MI
CY2020	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	48108
CY2020	dei	City Area Code CityAreaCode	734
CY2020	dei	Local Phone Number LocalPhoneNumber	887-3903
CY2020	dei	Security12b Title Security12bTitle	Common Stock, $0.001 par value
CY2020	dei	Trading Symbol TradingSymbol	ESPR
CY2020	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2020	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	Yes
CY2020	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2020	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2020	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2020	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2020	dei	Entity Small Business EntitySmallBusiness	false
CY2020	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2020	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	true
CY2020	dei	Entity Shell Company EntityShellCompany	false
CY2020Q2	dei	Entity Public Float EntityPublicFloat	1410000000	USD
CY2021Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	27942612	shares
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	304962000	USD
CY2019Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	166130000	USD
CY2020Q4	us-gaap	Restricted Cash RestrictedCash	0	USD
CY2019Q4	us-gaap	Restricted Cash RestrictedCash	928000	USD
CY2020Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	0	USD
CY2019Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	34651000	USD
CY2020Q4	espr	Prepaid Clinical Development Costs Current PrepaidClinicalDevelopmentCostsCurrent	844000	USD
CY2019Q4	espr	Prepaid Clinical Development Costs Current PrepaidClinicalDevelopmentCostsCurrent	6081000	USD
CY2020Q4	us-gaap	Inventory Net InventoryNet	16136000	USD
CY2019Q4	us-gaap	Inventory Net InventoryNet	0	USD
CY2020Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	23954000	USD
CY2019Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	3924000	USD
CY2020Q4	us-gaap	Assets Current AssetsCurrent	345896000	USD
CY2019Q4	us-gaap	Assets Current AssetsCurrent	211714000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1276000	USD
CY2019Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1145000	USD
CY2020Q4	us-gaap	Indefinite Lived Intangible Assets Excluding Goodwill IndefiniteLivedIntangibleAssetsExcludingGoodwill	56000	USD
CY2019Q4	us-gaap	Indefinite Lived Intangible Assets Excluding Goodwill IndefiniteLivedIntangibleAssetsExcludingGoodwill	56000	USD
CY2020Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	6030000	USD
CY2019Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1532000	USD
CY2020Q4	us-gaap	Assets Assets	353258000	USD
CY2019Q4	us-gaap	Assets Assets	214447000	USD
CY2020Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	51975000	USD
CY2019Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	28856000	USD
CY2020Q4	espr	Accrued Clinical Development Costs Current AccruedClinicalDevelopmentCostsCurrent	7663000	USD
CY2019Q4	espr	Accrued Clinical Development Costs Current AccruedClinicalDevelopmentCostsCurrent	17511000	USD
CY2020Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	24790000	USD
CY2019Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	11871000	USD
CY2020Q4	espr	Revenue Interest Liability Current RevenueInterestLiabilityCurrent	5392000	USD
CY2019Q4	espr	Revenue Interest Liability Current RevenueInterestLiabilityCurrent	5236000	USD
CY2020Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	1662000	USD
CY2019Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	2152000	USD
CY2020Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	2587000	USD
CY2019Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	454000	USD
CY2020Q4	us-gaap	Liabilities Current LiabilitiesCurrent	94069000	USD
CY2019Q4	us-gaap	Liabilities Current LiabilitiesCurrent	66080000	USD
CY2020Q4	us-gaap	Convertible Long Term Notes Payable ConvertibleLongTermNotesPayable	179367000	USD
CY2019Q4	us-gaap	Convertible Long Term Notes Payable ConvertibleLongTermNotesPayable	0	USD
CY2020Q4	espr	Revenue Interest Liability Noncurrent RevenueInterestLiabilityNoncurrent	171212000	USD
CY2019Q4	espr	Revenue Interest Liability Noncurrent RevenueInterestLiabilityNoncurrent	127308000	USD
CY2020Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	3454000	USD
CY2019Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1109000	USD
CY2020Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	1290000	USD
CY2019Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	0	USD
CY2020Q4	us-gaap	Liabilities Liabilities	449392000	USD
CY2019Q4	us-gaap	Liabilities Liabilities	194497000	USD
CY2020Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2019Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2019Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2020Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2020Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2019Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2020Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2020Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2019Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2019Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2020Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2019Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2020Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2019Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2019Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	120000000	shares
CY2020Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	120000000	shares
CY2020Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	27910366	shares
CY2019Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	27497911	shares
CY2019Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	27497911	shares
CY2020Q4	us-gaap	Common Stock Value CommonStockValue	26000	USD
CY2019Q4	us-gaap	Common Stock Value CommonStockValue	27000	USD
CY2020Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	797655000	USD
CY2019Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	715166000	USD
CY2020Q4	us-gaap	Treasury Stock Shares TreasuryStockShares	1994198	shares
CY2020Q4	us-gaap	Treasury Stock Value TreasuryStockValue	54998000	USD
CY2019Q4	us-gaap	Treasury Stock Value TreasuryStockValue	0	USD
CY2020Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	0	USD
CY2019Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	23000	USD
CY2020Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-838817000	USD
CY2019Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-695266000	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	-96134000	USD
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	19950000	USD
CY2020Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	353258000	USD
CY2019Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	214447000	USD
CY2020	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	227547000	USD
CY2019	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	148364000	USD
CY2018	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	0	USD
CY2020	us-gaap	Other Cost And Expense Operating OtherCostAndExpenseOperating	2392000	USD
CY2019	us-gaap	Other Cost And Expense Operating OtherCostAndExpenseOperating	0	USD
CY2018	us-gaap	Other Cost And Expense Operating OtherCostAndExpenseOperating	0	USD
CY2020	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	146936000	USD
CY2019	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	175611000	USD
CY2018	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	171488000	USD
CY2020	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	199615000	USD
CY2019	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	65854000	USD
CY2018	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	33097000	USD
CY2020	us-gaap	Operating Expenses OperatingExpenses	348943000	USD
CY2019	us-gaap	Operating Expenses OperatingExpenses	241465000	USD
CY2018	us-gaap	Operating Expenses OperatingExpenses	204585000	USD
CY2020	us-gaap	Operating Income Loss OperatingIncomeLoss	-121396000	USD
CY2019	us-gaap	Operating Income Loss OperatingIncomeLoss	-93101000	USD
CY2018	us-gaap	Operating Income Loss OperatingIncomeLoss	-204585000	USD
CY2020	us-gaap	Interest Expense InterestExpense	22670000	USD
CY2019	us-gaap	Interest Expense InterestExpense	8120000	USD
CY2018	us-gaap	Interest Expense InterestExpense	28000	USD
CY2020	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	515000	USD
CY2019	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	4056000	USD
CY2018	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	2803000	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-143551000	USD
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-97165000	USD
CY2018	us-gaap	Net Income Loss NetIncomeLoss	-201810000	USD
CY2020	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-5.23
CY2019	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-3.59
CY2018	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-7.54
CY2020	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	27473873	shares
CY2019	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	27090284	shares
CY2018	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	26754308	shares
CY2020	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	-23000	USD
CY2019	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	342000	USD
CY2018	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	526000	USD
CY2020	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-143574000	USD
CY2019	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-96823000	USD
CY2018	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-201284000	USD
CY2017Q4	us-gaap	Stockholders Equity StockholdersEquity	244691000	USD
CY2018	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	11743000	USD
CY2018	espr	Stock Issued During Period Value Warrants Exercised StockIssuedDuringPeriodValueWarrantsExercised	0	USD
CY2018	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross	0	USD
CY2018	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	23968000	USD
CY2018	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	526000	USD
CY2018	us-gaap	Net Income Loss NetIncomeLoss	-201810000	USD
CY2018Q4	us-gaap	Stockholders Equity StockholdersEquity	79118000	USD
CY2019	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	11771000	USD
CY2019	espr	Stock Issued During Period Value Warrants Exercised StockIssuedDuringPeriodValueWarrantsExercised	0	USD
CY2019	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross	0	USD
CY2019	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	25884000	USD
CY2019	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	342000	USD
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-97165000	USD
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	19950000	USD
CY2020	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	6634000	USD
CY2020	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross	0	USD
CY2020	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	28385000	USD
CY2020	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-23000	USD
CY2020	us-gaap	Adjustments To Additional Paid In Capital Equity Component Of Convertible Debt AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt	93475000	USD
CY2020	us-gaap	Treasury Stock Value Acquired Cost Method TreasuryStockValueAcquiredCostMethod	55000000	USD
CY2020	espr	Adjustments To Additional Paid In Capital Capped Call Options Associated With Convertible Notes AdjustmentsToAdditionalPaidInCapitalCappedCallOptionsAssociatedWithConvertibleNotes	46004000	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-143551000	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	-96134000	USD
CY2020	us-gaap	Profit Loss ProfitLoss	-143551000	USD
CY2019	us-gaap	Profit Loss ProfitLoss	-97165000	USD
CY2018	us-gaap	Profit Loss ProfitLoss	-201810000	USD
CY2020	us-gaap	Depreciation Depreciation	547000	USD
CY2019	us-gaap	Depreciation Depreciation	319000	USD
CY2018	us-gaap	Depreciation Depreciation	265000	USD
CY2020	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	97000	USD
CY2019	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	200000	USD
CY2018	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	217000	USD
CY2020	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	1741000	USD
CY2019	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	0	USD
CY2018	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	0	USD
CY2020	us-gaap	Research And Development Asset Acquired Other Than Through Business Combination Written Off ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff	12500000	USD
CY2019	us-gaap	Research And Development Asset Acquired Other Than Through Business Combination Written Off ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff	0	USD
CY2018	us-gaap	Research And Development Asset Acquired Other Than Through Business Combination Written Off ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff	0	USD
CY2020	espr	Non Cash Interest Expense Related To Revenue Interest Liability NonCashInterestExpenseRelatedToRevenueInterestLiability	19560000	USD
CY2019	espr	Non Cash Interest Expense Related To Revenue Interest Liability NonCashInterestExpenseRelatedToRevenueInterestLiability	8120000	USD
CY2018	espr	Non Cash Interest Expense Related To Revenue Interest Liability NonCashInterestExpenseRelatedToRevenueInterestLiability	0	USD
CY2020	us-gaap	Share Based Compensation ShareBasedCompensation	28385000	USD
CY2019	us-gaap	Share Based Compensation ShareBasedCompensation	25884000	USD
CY2018	us-gaap	Share Based Compensation ShareBasedCompensation	23968000	USD
CY2020	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	14793000	USD
CY2019	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	3396000	USD
CY2018	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	2884000	USD
CY2020	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-490000	USD
CY2019	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	2152000	USD
CY2018	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	0	USD
CY2020	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	16136000	USD
CY2019	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	0	USD
CY2018	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	0	USD
CY2020	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	1290000	USD
CY2019	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	0	USD
CY2018	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	0	USD
CY2020	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	23106000	USD
CY2019	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-16055000	USD
CY2018	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	24446000	USD
CY2020	us-gaap	Increase Decrease In Other Accrued Liabilities IncreaseDecreaseInOtherAccruedLiabilities	2761000	USD
CY2019	us-gaap	Increase Decrease In Other Accrued Liabilities IncreaseDecreaseInOtherAccruedLiabilities	10000000	USD
CY2018	us-gaap	Increase Decrease In Other Accrued Liabilities IncreaseDecreaseInOtherAccruedLiabilities	7594000	USD
CY2020	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-85177000	USD
CY2019	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-70341000	USD
CY2018	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-148638000	USD
CY2020	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	4420000	USD
CY2019	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	34326000	USD
CY2018	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	25481000	USD
CY2020	espr	Payments To Acquire In Process Research And Development Other Than Through Business Combination PaymentsToAcquireInProcessResearchAndDevelopmentOtherThanThroughBusinessCombination	12500000	USD
CY2019	espr	Payments To Acquire In Process Research And Development Other Than Through Business Combination PaymentsToAcquireInProcessResearchAndDevelopmentOtherThanThroughBusinessCombination	0	USD
CY2018	espr	Payments To Acquire In Process Research And Development Other Than Through Business Combination PaymentsToAcquireInProcessResearchAndDevelopmentOtherThanThroughBusinessCombination	0	USD
CY2020	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	39145000	USD
CY2019	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	99510000	USD
CY2018	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	166081000	USD
CY2020	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	869000	USD
CY2019	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	953000	USD
CY2018	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	151000	USD
CY2020	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	21356000	USD
CY2019	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	64231000	USD
CY2018	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	140449000	USD
CY2020	us-gaap	Proceeds From Issuance Of Debt ProceedsFromIssuanceOfDebt	280000000	USD
CY2019	us-gaap	Proceeds From Issuance Of Debt ProceedsFromIssuanceOfDebt	0	USD
CY2018	us-gaap	Proceeds From Issuance Of Debt ProceedsFromIssuanceOfDebt	0	USD
CY2020	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	8405000	USD
CY2019	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	0	USD
CY2018	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	0	USD
CY2020	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	55000000	USD
CY2018	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	1049000	USD
CY2019	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	0	USD
CY2018	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	0	USD
CY2020	us-gaap	Payments For Derivative Instrument Financing Activities PaymentsForDerivativeInstrumentFinancingActivities	46004000	USD
CY2019	us-gaap	Payments For Derivative Instrument Financing Activities PaymentsForDerivativeInstrumentFinancingActivities	0	USD
CY2018	us-gaap	Payments For Derivative Instrument Financing Activities PaymentsForDerivativeInstrumentFinancingActivities	0	USD
CY2020	espr	Proceeds From Revenue Interest Purchase Agreement Net Of Issuance Costs ProceedsFromRevenueInterestPurchaseAgreementNetOfIssuanceCosts	25000000	USD
CY2019	espr	Proceeds From Revenue Interest Purchase Agreement Net Of Issuance Costs ProceedsFromRevenueInterestPurchaseAgreementNetOfIssuanceCosts	124424000	USD
CY2018	espr	Proceeds From Revenue Interest Purchase Agreement Net Of Issuance Costs ProceedsFromRevenueInterestPurchaseAgreementNetOfIssuanceCosts	0	USD
CY2020	espr	Payments On Revenue Interest Liability PaymentsOnRevenueInterestLiability	500000	USD
CY2019	espr	Payments On Revenue Interest Liability PaymentsOnRevenueInterestLiability	0	USD
CY2018	espr	Payments On Revenue Interest Liability PaymentsOnRevenueInterestLiability	0	USD
CY2020	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	6634000	USD
CY2019	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	11771000	USD
CY2018	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	11743000	USD
CY2020	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	0	USD
CY2019	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	0	USD
CY2020	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	201725000	USD
CY2019	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	136195000	USD
CY2018	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	10694000	USD
CY2020	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	137904000	USD
CY2019	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	130085000	USD
CY2018	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	2505000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	167058000	USD
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	36973000	USD
CY2017Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	34468000	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	304962000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	167058000	USD
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	36973000	USD
CY2020	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	0	USD
CY2019	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	190000	USD
CY2018	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	199000	USD
CY2020	espr	Non Cash Right Of Use Asset NonCashRightOfUseAsset	20000	USD
CY2019	espr	Non Cash Right Of Use Asset NonCashRightOfUseAsset	31000	USD
CY2018	espr	Non Cash Right Of Use Asset NonCashRightOfUseAsset	0	USD
CY2020	espr	Deferred Offering Costs Incurred DeferredOfferingCostsIncurred	495000	USD
CY2019	espr	Deferred Offering Costs Incurred DeferredOfferingCostsIncurred	0	USD
CY2018	espr	Deferred Offering Costs Incurred DeferredOfferingCostsIncurred	0	USD
CY2020	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in accordance with generally accepted accounting principles in the United States requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, net revenues, expenses and related disclosures. Actual results could differ from those estimates.</span></div>
CY2020	us-gaap	Advertising Expense AdvertisingExpense	19300000	USD
CY2020	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Concentration of Credit Risk</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash, cash equivalents, and marketable securities consist of financial instruments that potentially subject the Company to concentrations of credit risk. The Company has established guidelines for investment of its excess cash and believes the guidelines maintain safety and liquidity through diversification of counterparties and maturities. The Company enters into a limited number of distribution agreements with distributors and specialty pharmacies. The Company's net product sales are with these customers. As of December 31, 2020, eight customers accounted for all of the Company's net trade receivables.</span></div>
CY2020	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
CY2020	us-gaap	Asset Impairment Charges AssetImpairmentCharges	0	USD
CY2020	espr	Number Of Sources Of Revenue NumberOfSourcesOfRevenue	2	revenue_source
CY2019	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	148400000	USD
CY2019	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	148400000	USD
CY2020Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	13788000	USD
CY2019Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	0	USD
CY2020Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	2028000	USD
CY2019Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	0	USD
CY2020Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	320000	USD
CY2019Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	0	USD
CY2020Q4	us-gaap	Inventory Net InventoryNet	16136000	USD
CY2019Q4	us-gaap	Inventory Net InventoryNet	0	USD
CY2020Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	2847000	USD
CY2019Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	2176000	USD
CY2020Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	1571000	USD
CY2019Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	1031000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1276000	USD
CY2019Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1145000	USD
CY2020	us-gaap	Depreciation Depreciation	500000	USD
CY2019	us-gaap	Depreciation Depreciation	300000	USD
CY2018	us-gaap	Depreciation Depreciation	300000	USD
CY2020Q4	us-gaap	Accrued Employee Benefits Current AccruedEmployeeBenefitsCurrent	15161000	USD
CY2019Q4	us-gaap	Accrued Employee Benefits Current AccruedEmployeeBenefitsCurrent	7818000	USD
CY2020Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	3183000	USD
CY2019Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	3842000	USD
CY2019Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	211000	USD
CY2020Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	24790000	USD
CY2019Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	11871000	USD
CY2020Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	6446000	USD
CY2020Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	281783000	USD
CY2020Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	0	USD
CY2020Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	0	USD
CY2020Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	281783000	USD
CY2019Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	62589000	USD
CY2019Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	23000	USD
CY2019Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	0	USD
CY2019Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	62612000	USD
CY2020	espr	Fair Value Measurement Asset Transfers Between Levels FairValueMeasurementAssetTransfersBetweenLevels	0	USD
CY2020	espr	Fair Value Measurement Liability Transfers Between Levels FairValueMeasurementLiabilityTransfersBetweenLevels	0	USD
CY2019	espr	Fair Value Measurement Liability Transfers Between Levels FairValueMeasurementLiabilityTransfersBetweenLevels	0	USD
CY2019	espr	Fair Value Measurement Asset Transfers Between Levels FairValueMeasurementAssetTransfersBetweenLevels	0	USD
CY2020	espr	Revenue Interest Liability Increase For Funding Received RevenueInterestLiabilityIncreaseForFundingReceived	25000000	USD
CY2020Q4	us-gaap	Payments For Derivative Instrument Financing Activities PaymentsForDerivativeInstrumentFinancingActivities	46000000.0	USD
CY2020Q4	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	55000000.0	USD
CY2020Q4	us-gaap	Payments For Derivative Instrument Financing Activities PaymentsForDerivativeInstrumentFinancingActivities	46000000.0	USD
CY2020Q4	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	55000000.0	USD
CY2020Q4	us-gaap	Treasury Stock Shares Acquired TreasuryStockSharesAcquired	1994198	shares
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	4677929	shares
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	39.31
CY2019	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P6Y9M25D
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	109054000	USD
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	234940	shares
CY2020	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	61.14
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	436916	shares
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	53.95
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	6300000	USD
CY2020	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	299435	shares
CY2020	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	22.15
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	4176518	shares
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	40.24
CY2020	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P5Y3M10D
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	18415000	USD
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	4176518	shares
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	40.24
CY2020	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P5Y3M10D
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	18415000	USD
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	3356739	shares
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	36.96
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.73
CY2020	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P4Y7M13D
CY2020Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	18154000	USD
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	17700000	USD
CY2018	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	12100000	USD
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0170
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0210
CY2018	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0275
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2018	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2020	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y3M
CY2019	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y3M
CY2018	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y2M15D
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.81
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	31.18
CY2018	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	37.56
CY2018	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.72
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	43.22
CY2020	us-gaap	Operating Lease Cost OperatingLeaseCost	2200000	USD
CY2020Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	26800000	USD
CY2020	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	2700000	USD
CY2019	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	700000	USD
CY2018	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	300000	USD
CY2020	espr	Operating Lease Increase Decrease In Right Of Use Assets OperatingLeaseIncreaseDecreaseInRightOfUseAssets	4500000	USD
CY2019	espr	Operating Lease Increase Decrease In Operating Lease Liabilities OperatingLeaseIncreaseDecreaseInOperatingLeaseLiabilities	4500000	USD
CY2020	us-gaap	Operating Lease Payments OperatingLeasePayments	2200000	USD
CY2019	us-gaap	Operating Lease Payments OperatingLeasePayments	300000	USD
CY2019	us-gaap	Operating Lease Cost OperatingLeaseCost	300000	USD
CY2020Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P2Y3M18D
CY2019Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P3Y3M18D
CY2020Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.035
CY2019Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.065
CY2020	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	0	USD
CY2019	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	0	USD
CY2018	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	300000	USD
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	2746000	USD
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	2711000	USD
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	830000	USD
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	6287000	USD
CY2020Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	246000	USD
CY2020Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	6041000	USD
CY2020Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	6030000	USD
CY2020Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	2587000	USD
CY2020Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	3454000	USD
CY2020Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	6041000	USD
CY2018	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2019	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2020Q4	espr	Deferred Tax Assets Net Of Deferred Tax Liabilities Before Valuation Allowance DeferredTaxAssetsNetOfDeferredTaxLiabilitiesBeforeValuationAllowance	202800000	USD
CY2019Q4	espr	Deferred Tax Assets Net Of Deferred Tax Liabilities Before Valuation Allowance DeferredTaxAssetsNetOfDeferredTaxLiabilitiesBeforeValuationAllowance	174200000	USD
CY2018Q4	espr	Deferred Tax Assets Net Of Deferred Tax Liabilities Before Valuation Allowance DeferredTaxAssetsNetOfDeferredTaxLiabilitiesBeforeValuationAllowance	152200000	USD
CY2019	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2020	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2018	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate	0
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate	0.002
CY2018	us-gaap	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate	0
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense EffectiveIncomeTaxRateReconciliationNondeductibleExpense	-0.006
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense EffectiveIncomeTaxRateReconciliationNondeductibleExpense	0.010
CY2018	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense EffectiveIncomeTaxRateReconciliationNondeductibleExpense	0.005
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits EffectiveIncomeTaxRateReconciliationTaxCredits	-0.163
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits EffectiveIncomeTaxRateReconciliationTaxCredits	0
CY2018	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits EffectiveIncomeTaxRateReconciliationTaxCredits	0
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.008
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.007
CY2018	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.005
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.359
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.215
CY2019Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	2089000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	227797000	USD
CY2020	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.000
CY2019	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.000
CY2018	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.000
CY2018	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.210
CY2020Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	2600000	USD
CY2019Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0	USD
CY2020Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	172530000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	154912000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	21454000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	17217000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	23452000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	0	USD
CY2020Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	10361000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	174218000	USD
CY2020Q4	espr	Deferred Tax Liabilities Convertible Debt DeferredTaxLiabilitiesConvertibleDebt	24795000	USD
CY2019Q4	espr	Deferred Tax Liabilities Convertible Debt DeferredTaxLiabilitiesConvertibleDebt	0	USD
CY2020Q4	us-gaap	Deferred Tax Liabilities Other DeferredTaxLiabilitiesOther	159000	USD
CY2019Q4	us-gaap	Deferred Tax Liabilities Other DeferredTaxLiabilitiesOther	0	USD
CY2020Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	24954000	USD
CY2019Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	0	USD
CY2020Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	202843000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	174218000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0	USD
CY2019Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0	USD
CY2020	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	13054817	shares
CY2019	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	4923895	shares
CY2018	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	5349428	shares
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	304962000	USD
CY2019Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	166130000	USD
CY2020Q4	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	0	USD
CY2019Q4	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	928000	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	304962000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	167058000	USD
CY2020Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	1840000	USD
CY2020Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	212236000	USD
CY2020Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	3833000	USD
CY2020Q4	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	9638000	USD
CY2020Q1	us-gaap	Other Cost And Expense Operating OtherCostAndExpenseOperating	31000	USD
CY2020Q2	us-gaap	Other Cost And Expense Operating OtherCostAndExpenseOperating	398000	USD
CY2020Q3	us-gaap	Other Cost And Expense Operating OtherCostAndExpenseOperating	275000	USD
CY2020Q4	us-gaap	Other Cost And Expense Operating OtherCostAndExpenseOperating	1688000	USD
CY2020Q1	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	34702000	USD
CY2020Q2	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	34987000	USD
CY2020Q3	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	35283000	USD
CY2020Q4	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	41964000	USD
CY2020Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	41553000	USD
CY2020Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	81000	USD
CY2020Q2	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	47681000	USD
CY2020Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	48826000	USD
CY2020Q4	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	61555000	USD
CY2020Q1	us-gaap	Operating Expenses OperatingExpenses	76286000	USD
CY2020Q2	us-gaap	Operating Expenses OperatingExpenses	83066000	USD
CY2020Q3	us-gaap	Operating Expenses OperatingExpenses	84384000	USD
CY2020Q4	us-gaap	Operating Expenses OperatingExpenses	105207000	USD
CY2020Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-74446000	USD
CY2020Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	129170000	USD
CY2020Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-80551000	USD
CY2020Q4	us-gaap	Operating Income Loss OperatingIncomeLoss	-95569000	USD
CY2020Q1	us-gaap	Interest Expense InterestExpense	4171000	USD
CY2020Q2	us-gaap	Interest Expense InterestExpense	4640000	USD
CY2020Q3	us-gaap	Interest Expense InterestExpense	4928000	USD
CY2020Q4	us-gaap	Interest Expense InterestExpense	8931000	USD
CY2020Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	368000	USD
CY2020Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	42000	USD
CY2020Q4	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	24000	USD
CY2020Q1	us-gaap	Net Income Loss NetIncomeLoss	-78249000	USD
CY2020Q2	us-gaap	Net Income Loss NetIncomeLoss	124611000	USD
CY2020Q3	us-gaap	Net Income Loss NetIncomeLoss	-85437000	USD
CY2020Q4	us-gaap	Net Income Loss NetIncomeLoss	-104476000	USD
CY2020Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.84
CY2020Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	4.50
CY2020Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-3.07
CY2020Q4	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-3.89
CY2020Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-2.84
CY2020Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	4.32
CY2020Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-3.07
CY2020Q4	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-3.89
CY2020Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	27519229	shares
CY2020Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	27665728	shares
CY2019Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	1387000	USD
CY2020Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	27830281	shares
CY2020Q4	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	26882830	shares
CY2020Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	27519229	shares
CY2020Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	28854445	shares
CY2020Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	27830281	shares
CY2020Q4	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	26882830	shares
CY2019Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	145419000	USD
CY2019Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	982000	USD
CY2019Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	981000	USD
CY2019Q4	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	982000	USD
CY2019Q1	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	46308000	USD
CY2019Q2	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	42788000	USD
CY2019Q3	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	48281000	USD
CY2019Q4	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	38234000	USD
CY2019Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	12182000	USD
CY2019Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	13492000	USD
CY2019Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	18468000	USD
CY2019Q4	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	21712000	USD
CY2019Q1	us-gaap	Operating Expenses OperatingExpenses	58490000	USD
CY2019Q2	us-gaap	Operating Expenses OperatingExpenses	56280000	USD
CY2019Q3	us-gaap	Operating Expenses OperatingExpenses	66749000	USD
CY2019Q4	us-gaap	Operating Expenses OperatingExpenses	59946000	USD
CY2019Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	86929000	USD
CY2019Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-55298000	USD
CY2019Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-65768000	USD
CY2019Q4	us-gaap	Operating Income Loss OperatingIncomeLoss	-58964000	USD
CY2019Q1	us-gaap	Interest Expense InterestExpense	0	USD
CY2019Q2	us-gaap	Interest Expense InterestExpense	0	USD
CY2019Q3	us-gaap	Interest Expense InterestExpense	3996000	USD
CY2019Q4	us-gaap	Interest Expense InterestExpense	4124000	USD
CY2019Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	450000	USD
CY2019Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	1077000	USD
CY2019Q4	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	1142000	USD
CY2019Q1	us-gaap	Net Income Loss NetIncomeLoss	87379000	USD
CY2019Q2	us-gaap	Net Income Loss NetIncomeLoss	-54221000	USD
CY2019Q3	us-gaap	Net Income Loss NetIncomeLoss	-68377000	USD
CY2019Q4	us-gaap	Net Income Loss NetIncomeLoss	-61946000	USD
CY2019Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	3.26
CY2019Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.01
CY2019Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.52
CY2019Q4	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.26
CY2019Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	3.07
CY2019Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-2.01
CY2019Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-2.52
CY2019Q4	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-2.26
CY2019Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	26842785	shares
CY2019Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	26968818	shares
CY2019Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	27171769	shares
CY2019Q4	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	27371067	shares
CY2019Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	28449767	shares
CY2019Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	26968818	shares
CY2019Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	27171769	shares
CY2019Q4	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	27371067	shares

Files In Submission

Name	View Source	Status
0001628280-21-002865-index-headers.html	Edgar Link	pending
0001628280-21-002865-index.html	Edgar Link	pending
0001628280-21-002865.txt	Edgar Link	pending
0001628280-21-002865-xbrl.zip	Edgar Link	pending
espr-20201231.htm	Edgar Link	pending
espr-20201231.xsd	Edgar Link	pending
espr-20201231_cal.xml	Edgar Link	unprocessable
espr-20201231_def.xml	Edgar Link	unprocessable
espr-20201231_g1.jpg	Edgar Link	pending
espr-20201231_htm.xml	Edgar Link	completed
espr-20201231_lab.xml	Edgar Link	unprocessable
espr-20201231_pre.xml	Edgar Link	unprocessable
ex-1022oberlandamendment.htm	Edgar Link	pending
ex-1023koenigemploymentagr.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
ex-1024hallemploymentagree.htm	Edgar Link	pending
ex-231.htm	Edgar Link	pending
ex-311.htm	Edgar Link	pending
ex-312.htm	Edgar Link	pending
ex-321.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ESPR
Esperion Therapeutics, Inc. Stock $espr

2020 Q4 Form 10-K Financial Statement

#000162828021002865 Filed on February 23, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ESPR Esperion Therapeutics, Inc. Stock $espr

2020 Q4 Form 10-K Financial Statement

#000162828021002865 Filed on February 23, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ESPR
Esperion Therapeutics, Inc. Stock $espr